As a result, great emphasis has been placed on neoadjuvant chemoradiotherapy, with predominant features in accurate target volume delineation, low complication rates of organs at risk, low tumor load before surgeries and prevention of the delay of postoperative treatment. Therefore, the inappropriate locally advanced pancreatic cancer patients (30%-80%) for surgeries can be operated via neoadjuvant chemoradiotherapy. Nevertheless, long durations of conventional radiotherapy results in delay of the thereafter treatment.